JPRN-UMIN000000548已完成未知
Assessment of Beta-Blocker Treatment in Japanese Patients with Chronic Heart Failure - J-CHF
J-CHF Study Group0 个研究点目标入组 480 人开始时间: 2006年12月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 480
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Primary illness of valvular stenosis, or severe valvular regurgitation. 2) Hypertrophic occlusive cardiomyopathy, restrictive cardiomyopathy, right ventricular cardiomyopathy of arrhythmic origin, or progressive myocarditis 3) Cardiogenic shock patients or patients with systolic blood pressure less than 80mmHg. 4) Severe arrhythmia, bradycardia (>=50 beats/min), or second-degree or higher atrioventricular block. However, cases of temporary bradycardia and Wenckebach second-degree atrioventricular block left to the judgment of the treating physician. 5) Acute myocardial infarction within 3 months prior to the date of consent. 6) Unstable angina pectoris or coronary spasm/rest angina. 7) CABG or PCI within 3 months prior to the date of consent, or patients scheduled for CABG or PCI during the study period. 8) Cerebrovascular accident within 6 months prior to the date of consent. 9) Bronchial asthma or other such chronic respiratory illness, or cor pulmonale. 10) History of malignant tumor or other such life-threatening illness of poor prognosis within 5 years prior to the date of consent. 11) Arteriosclerosis obliterans patients (Fontaine Class 2 or higher). 12) Poorly controlled diabetes. 13) Severe complication by any of the following illnesses: kidney disease , liver disease , anemia. 14) Thyroid dysfunction poorly controlled by treatment. 15) Pregnant, lactating, or possibly pregnant or desiring to become pregnant during the study period. 16) History of drug hypersensitivity to carvedilol. 17) Carvedilol administration is deemed contraindicated. 18) Written consent is not obtained. 19) Other patients deemed unsuitable as subjects of the study by the treating physician.
研究者
相似试验
已完成
2 期
Phase II Clinical Study of BTDS in Japanese Patients with Cancer PaiCancer painJPRN-jRCT2080223363Mundipharma K.K.70
招募中
2 期
Modified Apixaban in Japanese Patients with Cancer-Associated Venous Thromboembolismcancer-associated thromboembolismmalignancy, cancer-associated thromboembolism, CAT, CA-VTEJPRN-jRCTs051220095Minami Hironobu80
已完成
1 期
A Phase 1/2 Study of Zanubrutinib in Japanese Patients With Mature B-Cell MalignanciesJPRN-jRCT2080224959BeiGene, Ltd.62
已完成
不适用
Clinical outcome of pazopanib in Japanese patients with soft tissue sarcoma; Multicenter studyMalignant soft tissue tumorJPRN-UMIN000012561Japanese Musculoskeletal Oncology Group200
已完成
不适用
Efficacy and Safety of Nintedanib in Japanese patients with early stage of idiopathic pulmonary fibrosisIdiopathic pulmonary fibrosis (IPF)JPRN-UMIN000038192Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences215